MediciNova Overview

  • Founded
  • 2000

Founded
  • Status
  • Public

  • Employees
  • 11

Employees
  • Stock Symbol
  • MNOV

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $2.40

  • (As of Thursday Closing)

MediciNova General Information

Description

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 4275 Executive Square
  • Suite 300
  • La Jolla, CA 92037
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MediciNova Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.40 $2.38 $2.09 - $4.65 $117M 49M 24.6K -$0.26

MediciNova Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 56,556 56,561 174,658 232,622
Revenue 38 4,038 0 0
EBITDA (13,254) (10,249) (14,195) (14,053)
Net Income (13,078) (10,134) (13,854) (12,942)
Total Assets 81,236 87,406 75,419 79,205
Total Debt 184 132 186 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MediciNova Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MediciNova‘s full profile, request access.

Request a free trial

MediciNova Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore MediciNova‘s full profile, request access.

Request a free trial

MediciNova Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the tre
Pharmaceuticals
La Jolla, CA
11 As of 2021
00000
000000000 00000

000000

m ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat
0000 000000000
Gaithersburg, MD
00 As of 0000
000.00
000000 - 000 000.00

000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000 000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MediciNova Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altimmune Corporate Backed or Acquired Gaithersburg, MD 00 000.00 000000 - 000 000.00
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
You’re viewing 5 of 42 competitors. Get the full list »

MediciNova Patents

MediciNova Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210308109-A1 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients Pending 06-Apr-2020 0000000000
EP-4034090-A1 Ibudilast oral formulations and methods of using same Pending 23-Sep-2019 0000000000
US-20210085613-A1 Ibudilast oral formulations and methods of using same Pending 23-Sep-2019 0000000000
US-11154540-B2 Methods of treating ophthalmic disease/disorder or injury with ibudilast Active 19-Oct-2018 0000000000 0
US-20200121659-A1 Methods of treating ophthalmic disease/disorder or injury with ibudilast Granted 19-Oct-2018 A61K31/4355
To view MediciNova’s complete patent history, request access »

MediciNova Executive Team (14)

Name Title Board Seat Contact Info
Yuichi Iwaki MD Chief Executive Officer & Board Member
Jason Kruger Chief Financial Officer, Finance
Geoffrey O'Brien JD Vice President
Kazuko Matsuda Ph.D Chief Medical Officer & Board Member
David Crean Ph.D Executive
You’re viewing 5 of 14 executive team members. Get the full list »

MediciNova Board Members (12)

Name Representing Role Since
Carolyn Beaver MediciNova Board Member 000 0000
Hideki Nagao MediciNova Board Member 000 0000
Jeff Himawan Ph.D EW Healthcare Partners Chairman & Board Member 000 0000
Kazuko Matsuda Ph.D MediciNova Chief Medical Officer & Board Member 000 0000
Yuichi Iwaki MD MediciNova Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

MediciNova Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MediciNova Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MediciNova‘s full profile, request access.

Request a free trial

MediciNova Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 18-Dec-2009 0000000000 000.00 Biotechnology 000000 00
To view MediciNova’s complete acquisitions history, request access »